Navigation Links
Bionovo Announces First Quarter 2009 Highlights and Financial Results
Date:5/7/2009

EMERYVILLE, Calif., May 7 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced first quarter highlights and financial results for the three months ended March 31, 2009.

Company Highlights

  • Bionovo presented data on a preclinical anti-cancer drug candidate, BN108, at the American Association of Cancer Research (AACR) conference in April. TspA3 has been identified as an active compound of BN108 that is responsible for BN108's selective cytotoxicity. BN108 and TspA3 induce apoptosis through rapid inactivation of AKT and mTOR kinases in breast cancer cells but not in normal cells.
  • Two additional members joined Bionovo's Scientific Advisory Board, Jan-Ake Gustafsson and Bert W. O'Malley.
  • The Company continues to work towards satisfying the FDA's requests for clarification of the manufacturing and analytical strategy to be used in ensuring the consistency of its drug products.
  • The Company continues to pursue a wide variety of funding options including government grants, partnering, and debt and equity offerings.

First Quarter Results

Total operating expenses for the three months ending March 31, 2009 were $4.6 million compared to $4.2 million for the same period in 2008. Total operating expenses for the first quarter included one-time expenses associated with the relocation of the Company's headquarters, the purchase of raw materials for manufacturing purposes throughout the year, and severance costs. The Company expects operating expenses to decrease in the second quarter.

The Company reported a net loss for the three months ended March 31, 2009 of $4.7 million, or $0.06 per share, compared with a net loss of $3.9 million, or $0.05 per share,
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
2. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
3. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
4. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
5. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
8. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
9. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
10. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
11. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... , Switzerland , February 9 ... global biopharmaceutical group of companies with,a focus ... target unmet medical,needs, today announced the signature ... the development, manufacture and commercialisation of Debio ... with a,potent anti-hepatitis C virus (HCV) effect. ...
(Date:2/8/2010)... PreXion, Inc., ( www.prexion.com ) the ... for dentistry, today announced that it has appointed ... PreXion President/COO Robert Meier commented, "We are ... and I look forward to working with him in ... and success in the dental and high tech medical ...
(Date:2/8/2010)... Feb. 8 Rapid developments ... steady increase in the use and cost of ... arthritis and psoriasis. This has led to some ... costs and medication coverage being spread over both ... new solution with Medication Cost Integration (MCI), which ...
Breaking Medicine Technology:Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 2Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 3PreXion, Inc. Announces Appointment of Director of Marketing 2RegenceRx Leads the Industry With Introduction of Medication Cost Integration 2RegenceRx Leads the Industry With Introduction of Medication Cost Integration 3Doctor Building Nutritarian Army to Fight Disease 65240 1Doctor Building Nutritarian Army to Fight Disease 65240 2Doctor Building Nutritarian Army to Fight Disease 65240 3Hakuna Staff Scheduling Software is Proud To Announce the Launch of Its Online Employee Scheduling Program 65238 1Hakuna Staff Scheduling Software is Proud To Announce the Launch of Its Online Employee Scheduling Program 65238 2Endo and Jubilant Expand Oncology Discovery Partnership on Successful Delivery of Early Milestone 15419 1Endo and Jubilant Expand Oncology Discovery Partnership on Successful Delivery of Early Milestone 15419 2Endo and Jubilant Expand Oncology Discovery Partnership on Successful Delivery of Early Milestone 15419 3
... - Results from phase III,clinical trials and further ... of the European Academy of,Dermatology and Venereology (EADV). ... alitretinoin as a potential once,daily oral treatment for ... no approved treatment exists for severe Chronic Hand,Eczema ...
... MENLO PARK, Calif.--(BUSINESS WIRE)--May,21, 2007 - ChemGenex ... of new clinical data relevant to the ... and the T315I mutation in Philadelphia-positive leukemias",by ... University of,Bologna, Italy (Haematologica Volume 92, pages ...
Other Medicine Technology:Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 2Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 3Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 4Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 5Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 2Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 3
(Date:2/9/2010)... the Heart with "The Heart-Smart Diabetes ... 9 Show your love this ... the heart with the new cookbook "The Heart-Smart ... Canola Oil" by the American Diabetes Association (ADA) and ... love or give the cookbook as a gift, you ...
(Date:2/9/2010)... LA JOLLA, CA-- Dana-Farber Cancer Institute and the ... agreement with Genentech, a wholly owned member of ... companies exclusive rights to manufacture, develop and market ... group 1 influenza viruses. These viruses include the ... Genentech and Roche also have a non-exclusive right ...
(Date:2/9/2010)... Cancer Center of University Hospitals (UH) Case Medical Center, ... new standard of care for patients with locally advanced ... of Clinical Cancer Research, the phase one ... well tolerated in combination with standard-of-care cisplatin chemotherapy and ... provided both significant reduction in cancer disease and cancer ...
(Date:2/9/2010)... The research group of Dr. Franois Robert, a researcher ... in collaboration with the team of Dr. Daniel Durocher ... a technical breakthrough: they mapped all the fragile sites ... cerevisiae . The method used by the researchers can ... online today in the scientific journal Nature Structural ...
(Date:2/9/2010)... MINNEAPOLIS/ST.PAUL (February 8, 2010)- Consuming two or more soft ... cancer by nearly two-fold compared with individuals who did ... Cancer Epidemiology, Biomarkers & Prevention , a journal ... Although relatively rare, pancreatic cancer remains one of the ... diagnosed survive five years later. , Mark Pereira, Ph.D., ...
Breaking Medicine News(10 mins):Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 2Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 3Health News:Researchers map all the fragile sites of the yeast Saccharomyces cerevisiae's genome 2Health News:Researchers map all the fragile sites of the yeast Saccharomyces cerevisiae's genome 3Health News:Soft drinks may increase risk of pancreatic cancer 2
... CEO, American Association of,Homes and Services for the ... Exceptions Process, WASHINGTON, July 2 Following ... American Association of Homes and,Services for the Aging, ... Process:, "Medicare beneficiaries are once again having ...
... American Medical,Association Foundation announced the election today of ... of Traverse City, Michigan, is finishing her fifth ... is the first Alliance,representative to be President of ... President, President-Elect, Treasurer, Finance,Committee Chair, Secretary, Bylaws Committee ...
... water ... needed to fight fire, VANCOUVER, British Columbia, July 2 ... house fire, Shelter,Island Fire Department First Assistant Fire Chief William Rowland made ... FIT-5,a new handheld fire interruption device that quickly knocked down a,basement fire ...
... NORTH ANDOVER, Mass., July 2 Does your ... shows that upwards of 10.7,million pets in the ... unwanted behaviors. While the trend toward the use ... and other,complex stress-related emotions is on the rise, ...
... as most common reason for hospitalizations, analysis finds , , ... than 1.2 million Americans -- roughly equivalent to the ... federal government analysis of hospital admissions and costs found. ... most common reason for admission to hospital, and treating ...
... 2 David Belkin died,last February during a pick-up basketball ... alive to tell about it., On Sunday, July 6 ... present Matlaga with the Sudden Cardiac Arrest (SCA) Foundation,s,People Saving ... at,13 Hillcrest Rd. (behind Wayne Memorial Hospital) in Honesdale., ...
Other Medicine News:Health News:AAHSA Statement: Therapy Caps Ration Care 2Health News:AMA Foundation Names Jean Howard President 2Health News:Home in Prominent Shelter Island, New York, Ablaze; Saved by the FIT-5 Fire Fighting Device 2Health News:Natural Remedies to Treat Animals' Complex Emotions 2Health News:Back From the Dead: Cardiac Arrest Victim Salutes His Rescuer 2
... Healing Shoe offers the most advanced design ... allowing patients to maintain their mobility. Thanks ... even larger portion of the forefoot is ... heads and toes to heal faster. OrthoWedge ...
The choice for inclement weather. This boot provides both closed toe and heel with a moisture resistant vinyl upper....
Ideal for use with thinner casting materials such as polyester or fiberglass. Conforms to any casting material....
This lightweight cast boot features a sturdy canvas upper. The three layer EVA rocker outsole provides excellent shock absorption....
Medicine Products: